Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio A Emini

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Pediatric Blood & Cancer|March 27, 2015
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 studyMariane De Montalembert, Miguel R Abboud, Anne Fiquet, et al.
Bioorganic & Medicinal Chemistry Letters|March 12, 2004
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chainsDong-Ming Shen, Min Shu, Sander G Mills, et al.
The Pediatric Infectious Disease Journal|December 15, 2010
Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trialMatthew D Snape, Chaam L Klinger, Elvis D Daniels, et al.
Vaccine|August 7, 2004
Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeysJiang Fan, Xiaoping Liang, Melanie S Horton, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2005
Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic propertiesDooseop Kim, Liping Wang, Jeffrey J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2002
CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidinesChristopher L Lynch, Amy L Gentry, Jeffrey J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2003
1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chainsChristopher A Willoughby, Keith G Rosauer, Jeffery J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2002
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIVChristopher L Lynch, Jeffrey J Hale, Richard J Budhu, et al.
Journal of Virology|September 15, 2005
Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeysXiaoping Liang, Danilo R Casimiro, William A Schleif, et al.
Journal of Virology|June 14, 2003
Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag geneDanilo R Casimiro, Aimin Tang, Ling Chen, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Pediatric Blood & Cancer|March 27, 2015
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 studyMariane De Montalembert, Miguel R Abboud, Anne Fiquet, et al.
Bioorganic & Medicinal Chemistry Letters|March 12, 2004
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chainsDong-Ming Shen, Min Shu, Sander G Mills, et al.
The Pediatric Infectious Disease Journal|December 15, 2010
Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trialMatthew D Snape, Chaam L Klinger, Elvis D Daniels, et al.
Vaccine|August 7, 2004
Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeysJiang Fan, Xiaoping Liang, Melanie S Horton, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2005
Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic propertiesDooseop Kim, Liping Wang, Jeffrey J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2002
CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidinesChristopher L Lynch, Amy L Gentry, Jeffrey J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2003
1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chainsChristopher A Willoughby, Keith G Rosauer, Jeffery J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2002
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIVChristopher L Lynch, Jeffrey J Hale, Richard J Budhu, et al.
Journal of Virology|September 15, 2005
Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeysXiaoping Liang, Danilo R Casimiro, William A Schleif, et al.
Journal of Virology|June 14, 2003
Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag geneDanilo R Casimiro, Aimin Tang, Ling Chen, et al.
Pageof 9